Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $7
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $9 to $7.
Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $9 to $7.